Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in recurrent NSCLC
NCT00063154Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2003
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Primary endpoint: Objective Response Rate at 1 year. Started Jul 2003; status: completed.
02
Drugs
pertuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00063154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063154.